共 8 条
[1]
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre; double-blind; randomised phase 3 trial[J] Edward B Garon;Tudor-Eliade Ciuleanu;Oscar Arrieta;Kumar Prabhash;Konstantinos N Syrigos;Tuncay Goksel;Keunchil Park;Vera Gorbunova;Ruben Dario Kowalyszyn;Joanna Pikiel;Grzegorz Czyzewicz;Sergey V Orlov;Conrad R Lewanski;Michael Thomas;Paolo Bidoli;Shaker Dakh
[2]
Choline phosphate cytidylyltransferase‐α is a novel antigen detected by the anti‐ERCC1 antibody 8F1 with biomarker value in patients with lung and head and neck squamous cell carcinomas[J] Alec E. Vaezi;Gerold Bepler;Nikhil R. Bhagwat;Agnes Malysa;Jennifer M. Rubatt;Wei Chen;Brian L. Hood;Thomas P. Conrads;Lin Wang;Carolyn E. Kemp;Laura J. Niedernhofer Cancer 2014,
[3]
Immunotherapy for lung cancer: ongoing clinical trials[J] Sarah Declerck;Johan Vansteenkiste Future Oncol. 2014,
[4]
Activity and safety of crizotinib in patients with ALK -positive non-small-cell lung cancer: updated results from a phase 1 study[J] Lancet Oncology 2012,
[5]
Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer[J] Jin-Ji Yang;Hua-Jun Chen;Hong-Hong Yan;Xu-Chao Zhang;Qing Zhou;Jian Su;Zhen Wang;Chong-Rui Xu;Yi-Sheng Huang;Bin-Chao Wang;Xue-Ning Yang;Wen-Zhao Zhong;Qiang Nie;Ri-Qiang Liao;Ben-Yuan Jiang;Song Dong;Yi-Long Wu Lung Cancer 2012,
[6]
Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial[J] Mark A. Socinski;Igor Bondarenko;Nina A. Karaseva;Anatoly M. Makhson;Igor Vynnychenko;Isamu Okamoto;Jeremy K. Hon;Vera Hirsh;Paul Bhar;Hui Zhang;Jose L. Iglesias;Markus F. Renschler Journal of Clinical Oncology 2012,
[7]
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL; CTONG-0802): a multicentre; open-label; randomised; phase 3 study[J] Caicun Zhou;Yi-Long Wu;Gongyan Chen;Jifeng Feng;Xiao-Qing Liu;Changli Wang;Shucai Zhang;Jie Wang;Songwen Zhou;Shengxiang Ren;Shun Lu;Li Zhang;Chengping Hu;Chunhong Hu;Yi Luo;Lei Chen;Ming Ye;Jianan Huang;Xiuyi Zhi;Yiping Zhang;Qingyu Xiu;Jun Ma;Li Zhang;Changxuan You Lancet Oncology 2011,
[8]
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)[J] E.A. Eisenhauer;P. Therasse;J. Bogaerts;L.H. Schwartz;D. Sargent;R. Ford;J. Dancey;S. Arbuck;S. Gwyther;M. Mooney;L. Rubinstein;L. Shankar;L. Dodd;R. Kaplan;D. Lacombe;J. Verweij European Journal of Cancer 2008,